Search
LENSAR Inc
LNSRAdd to Watchlist
5.840USD
+0.130+2.28%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
70.67MMarket Cap
2.39P/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+2.28%
5 Days
-3.63%
1 Month
+3.00%
6 Months
-49.79%
Year to Date
-49.79%
1 Year
-54.34%
Key Figures
5.720Open
5.840High
86.70KVolume
2.39P/E TTM
LossP/E Dynamic
--Dividend TTM
0.72%Turnover Ratio
5.710Prev. Close
5.660Low
344.00KTurnover
LossP/E Static
6.55P/B
0.00%Div Yield TTM
42.24%ROA
13.74052wk High
0.27Volume Ratio
-31.40MNet Profit
12.10MShares
2.4434EPS TTM
0.88Beta
-16631.70%ROE
5.06052wk Low
3.15%Amplitude
45.82%Gross Margin
70.67MMarket Cap
-0.18Reward/Risk
2.93%Risk Rate
TradingKey Stock Score of LENSAR Inc
Currency: USD Updated: 2026-07-01Key Insights
LENSAR Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 62 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 8.50.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
LENSAR Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
LENSAR Inc Highlights
StrengthsRisks
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 52.17% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 64.16M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 64.16M.
Overvalued
The company’s latest PE is 2.39, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 6.68M shares, decreasing 4.88% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 1.04M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.29.
Analyst Rating
Based on
2
analysts
Strong Buy
Current Rating
8.500
Target Price
+48.86%
Upside Space
LENSAR Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
LENSAR Inc Info
LENSAR, Inc. is a commercial-stage medical device company. The Company is focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. Its product portfolio includes the LENSAR Laser System (LLS), and the ALLY Robotic Cataract Laser Treatment System (ALLY). The Company has developed its ALLY Robotic Cataract Laser System as a compact, ergonomic system utilizing a fast dual-modality laser and integrating artificial intelligence (AI) into proprietary imaging and software. ALLY is designed to transform cataract surgery by utilizing the Company’s advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes its proprietary Streamline software technology, designed to guide surgeons to achieve better outcomes.
Ticker SymbolLNSR
CompanyLENSAR Inc
CEOCurtis (Nicholas T)
Websitehttps://www.lensar.com/
Related Instruments
+2.62%
+2.41%
+1.57%
+1.18%
+1.73%
+1.30%
-0.50%
+1.27%
+7.60%
+0.88%
+0.39%
+0.89%
+1.92%
+1.70%
+3.09%
+2.12%
+1.08%
+1.78%
+0.41%
+0.78%Popular Instruments
52361.200
+106.900 (+0.20%)
29955.100
+155.800 (+0.52%)
7500.000
+24.500 (+0.33%)
14993.000
-362.000 (-2.36%)
69806.000
+321.000 (+0.46%)
6298.200
+22.800 (+0.36%)
67.664
-0.304 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.460
+24.690 (+0.61%)
FAQs
What is the current price of LENSAR Inc (LNSR)?
The current price of LENSAR Inc (LNSR) is 5.84.
What is the symbol of LENSAR Inc?
The ticker symbol of LENSAR Inc is LNSR.
What is the 52-week high of LENSAR Inc?
The 52-week high of LENSAR Inc is 13.74.
What is the 52-week low of LENSAR Inc?
The 52-week low of LENSAR Inc is 5.06.
What is the market capitalization of LENSAR Inc?
The market capitalization of LENSAR Inc is 70.67M.
Is LENSAR Inc (LNSR) currently rated as Buy, Hold, or Sell?
According to analysts, LENSAR Inc (LNSR) has an overall rating of STRONG BUY, with a price target of 8.50.
What is the Earnings Per Share (EPS TTM) of LENSAR Inc (LNSR)?
The Earnings Per Share (EPS TTM) of LENSAR Inc (LNSR) is -2.87.